MedPlus Health Services Limited (NSE:MEDPLUS)
India · Delayed Price · Currency is INR | Market Cap | 106.80B +9.2% |
| Revenue (ttm) | 65.38B +6.9% |
| Net Income | 2.07B +56.4% |
| EPS | 17.24 +56.4% |
| Shares Out | 120.05M |
| PE Ratio | 51.59 |
| Forward PE | 44.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,319 |
| Average Volume | 77,274 |
| Open | 870.00 |
| Previous Close | 868.90 |
| Day's Range | 870.00 - 895.00 |
| 52-Week Range | 732.00 - 1,045.30 |
| Beta | 0.43 |
| RSI | 57.64 |
| Earnings Date | May 20, 2026 |
About MedPlus Health Services
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing serv... [Read more]
Financial Performance
In fiscal year 2025, MedPlus Health Services's revenue was 61.36 billion, an increase of 9.09% compared to the previous year's 56.25 billion. Earnings were 1.50 billion, an increase of 129.59%.
Financial StatementsNews
MedPlus Health Services Transcript: Q3 25/26
Q3 FY26 saw robust revenue and EBITDA growth, strong store expansion, and a rising private label mix. Margins remained stable despite a one-off labor code charge, and management expects continued growth in stores and profitability, driven by private label and operational efficiencies.
MedPlus Health Services Transcript: Q2 25/26
Q2 FY26 saw 145 new stores added, revenue up 8.8% YoY, and private label sales at 21.5% of total. Diagnostic EBITDA margin improved to 15.3%. SSSG turned positive at 2.2%, with high single-digit growth targeted in two years.
MedPlus Health Services Transcript: Q1 25/26
Revenue grew 6.6% YoY on GMV, with private label share rising to 20.4% and gross margins improving. Net addition of 101 stores in Q1, targeting 600 new stores in FY26, and diagnostic segment EBITDA margin reached 13.6%.
MedPlus Health Services Transcript: Q4 24/25
Revenue grew to INR 61,361 million in FY25 with operating EBITDA margin at 4.5%. Private label share rose sharply, driving gross margin expansion, while 305 net stores were added and 600 more are targeted for FY26. SSG is expected in high single to low double digits.
MedPlus Health Services Transcript: Q3 24/25
Revenue grew 8.3% YoY to INR 15,614 million, with private label share rising to 19.6% and EBITDA margin at 5.1%. Store expansion and new warehouses support future growth, while mature stores maintain strong profitability. SSG is expected to remain at 4-5%.
MedPlus Health Services Transcript: Q2 24/25
Q2 FY25 saw 11.9% year-on-year revenue growth, margin expansion, and strong private-label uptake, with 108 net new stores and diagnostics turning profitable. Gross margin and private-label share are expected to rise further, with 400–450 net store additions targeted for the year.
MedPlus Health Services Transcript: Q1 24/25
Q1 FY25 revenue grew 15.9% year-over-year to INR 14,888 million, with private-label products now 15.8% of revenue and diagnostics turning EBITDA positive. Management maintains 20%+ growth guidance for FY25, expects margin normalization, and sees continued private-label expansion.